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Abstract
Cardiac hypertrophy is a well-established risk factor for cardiovascular morbidity and mortality. Activation of Gq/11-mediated
signaling is required for pressure overload-induced cardiomyocyte (CM) hypertrophy to develop. We previously showed
that among Regulators of G protein Signaling, RGS2 selectively inhibits Gq/11 signaling and its hypertrophic effects in
isolated CM. In this study, we generated transgenic mice with CM-specific, conditional RGS2 expression (dTG) to investigate
whether RGS2 overexpression can be used to attenuate Gq/11-mediated signaling and hypertrophy in vivo. Transverse aortic
constriction (TAC) induced a comparable rise in ventricular mass and ANF expression and corresponding hemodynamic
changes in dTG compared to wild types (WT), regardless of the TAC duration (1-8 wks) and timing of RGS2 expression (from
birth or adulthood). Inhibition of endothelin-1-induced Gq/11-mediated phospholipase C b activity in ventricles and atrial
appendages indicated functionality of transgenic RGS2. However, the inhibitory effect of transgenic RGS2 on Gq/11-
mediated PLCb activation differed between ventricles and atria: (i) in sham-operated dTG mice the magnitude of the
inhibitory effect was less pronounced in ventricles than in atria, and (ii) after TAC, negative regulation of Gq/11 signaling was
absent in ventricles but fully preserved in atria. Neither difference could be explained by differences in expression levels,
including marked RGS2 downregulation after TAC in left ventricle and atrium. Counter-regulatory changes in other Gq/11-
regulating RGS proteins (RGS4, RGS5, RGS6) and random insertion were also excluded as potential causes. Taken together,
despite ample evidence for a role of RGS2 in negatively regulating Gq/11 signaling and hypertrophy in CM, CM-specific RGS2
overexpression in transgenic mice in vivo did not lead to attenuate ventricular Gq/11-mediated signaling and hypertrophy in
response to pressure overload. Furthermore, our study suggests chamber-specific differences in the regulation of RGS2
functionality and potential future utility of the new transgenic model in mitigating Gq/11 signaling in the atria in vivo.
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Introduction
Myocardial growth is a response of the cardiac muscle to altered
conditions of hemodynamic load. Pathological hypertrophy (e.g.,
in response to excess hemodynamic workload, such as in volume
or pressure overload or after myocardial infarction) is a well-
established risk factor for cardiovascular morbidity and mortality
[1]. It is part of a remodeling response that often leads to
functional decompensation and development of overt heart failure
with an increased risk of sudden cardiac death.
Many signaling pathways are involved in triggering cardiac
hypertrophy in response to hemodynamic stress [2]. Signaling via
heterotrimeric Gq/11 proteins is required for pressure overload
hypertrophy to develop [3,4]. Gq/11 signaling can be negatively
regulated by Regulators of G protein Signaling (RGS proteins),
several of which are expressed in the heart [5]. RGS proteins
negatively regulate G protein-coupled receptor signaling by
accelerating signal termination via direct binding of the RGS
core domain to activated GTP-bound Ga subunits [6], which
leads to an increase in the intrinsic rate of Ga GTP hydrolysis [7].
In addition, RGS proteins can diminish signal production by
blocking effectors from access to Ga subunits [8,9].
The specificity of RGS proteins towards particular G proteins
varies between different RGS isoforms [5]. Among the RGS
proteins expressed in cardiac myocytes, the RGS2 isoform has
emerged as a selective negative regulator of Gq/11 signaling: In
contrast to olfactory cells [10], RGS2 does not directly inhibit
adenylate cyclase (AC) in adult ventricular myocytes [11]. RGS2
also does not inhibit muscarinic inhibitory Gi/o-mediated cAMP
regulation, which differentiates it from other Gq/11-regulating
RGS proteins in adult ventricular myocytes (such as RGS3, RGS4
and RGS5) [11]. Transgenic overexpression of RGS4 and RGS5
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hypertrophy but with very different functional consequences (i.e.,
rapid decompensation and increased mortality vs. moderate
improvement in contractile function, respectively) [12,13].
Despite the presence of other Gq/11-regulating RGS proteins,
loss-of-function studies in rat ventricular myocytes in vitro (via
RGS2 RNAi, [14]) and in mice in vivo (in a global RGS2
knockout model, [15]) demonstrated that endogenous RGS2 is
a functionally important negative regulator of Gq/11 signaling and
hypertrophy. Gain-of-function studies showed that RGS2 over-
expression in rat ventricular myocytes inhibits Gq/11-mediated
signaling and hypertrophy development in vitro [11,16].
The goal of the present study was to test whether cardiac-
specific transgenic overexpression of RGS2 in mice can be used to
attenuate the hypertrophic response to pressure overload by
inhibiting Gq/11-mediated signal transduction in vivo. To that end,
we generated a mouse model with cardiac-specific RGS2
expression, examined its hypertrophic response to transverse
aortic constriction (TAC) and investigated the effect of transgenic
RGS2 expression on endothelin-1 (ET-1) induced activation of
phospholipase C b (PLCb), the immediate downstream target of
Gq/11 proteins. Since transgenic phenotypes can vary depending
on the timing of transgene expression [17,18], we utilized
a conditional Tet-off binary model [19] to investigate the effects
of RGS2 when it was expressed conditionally as of adulthood or
constitutively, based on the intrinsic characteristics of the a-myosin
heavy chain (MHC) promoter used to drive transgene expression.
Results
Generation of the RGS2 Transgenic Mouse Model
Using a binary tetracycline-based, murine a-MHC promoter-
driven system [19], we generated two independent mouse models
(Figure 1A) with cardiac-specific and tetracycline-regulatable
expression of N-terminally FLAG-tagged RGS2. Most experi-
ments were conducted in Line 1 (L1) mice; where indicated select
findings were confirmed in a second line (L12). Figure 1A
illustrates RGS2 protein expression levels after crossbreeding each
RGS2 transgenic line with tTA TG mice. At 3 weeks of age and in
the absence of Dox (i.e., when tTA can bind to the Tet operon
embedded in the a-MHC promoter of the responder line [19]),
transgenic RGS2 protein was expressed in crude ventricular
homogenates from double RGS2/tTA transgenic mice (dTG)
only; no FLAG-RGS2 was detected in RGS2 TG (or tTA TG and
WT), indicating that the expression of RGS2 is strictly tTA-
dependent (Figure 1B). Expression of transgenic RGS2 protein
was cardiac-specific (Figure 1C) and equally detectable in
membrane and cytosolic fractions (Figure 1D).
We previously demonstrated that a FLAG tag at the N-terminus
of RGS2 does not affect the inhibitory effect of RGS2 on Gq/11-
mediated signaling [20]. Functionality of transgenic RGS2 was
confirmed by inhibition of endothelin-1 (ET-1)-induced PLCb
activity in ventricles from RGS2-expressing dTG mice compared
to single RGS2 TG mice (Figure 1E). To that end, we measured
total inositol phosphate (IP) formation as a reflection of PLCb
activity, the immediate downstream target of Gq/11. RGS2-
expressing dTG mice were healthy and showed no changes in
cardiac weight (data not shown) or morphology (Figure 1F) under
baseline conditions.
Comparing different Dox concentrations (100 to 1000 mg/kg),
we established the minimal Dox dosage (100 mg/kg) to fully
suppress RGS2 expression (shown after 4 days in Figure 1G,
panel a). In mice treated with Dox from gestation until 3 weeks
of age, RGS2 was fully re-expressed within 8 weeks after Dox
Figure 1. Transgenic RGS2 Protein is expressed in a cardiac-
specific, tTA-dependent, Dox-regulatable manner and is func-
tionally active. [A] Representative Western blot of crude ventricular
homogenates (10 mg/lane) from 3-months old double transgenes (dTG)
of two independent transgenic RGS2 lines (L1, L12). The blot was
probed with antibodies recognizing RGS2 and GAPDH, which was used
as loading control. [B–D] Western blots of crude ventricular homo-
genates from indicated genotypes obtained from Line 1 matings (B), of
crude organ homogenates from dTG mice only (C), and membrane and
cytosolic fractions from dTG ventricles (D). Each blot was probed with
an anti-FLAG antibody. Calsequestrin expression and Ponceau S stain
were used as controls (panels B and C/D, respectively). The arrow in
panel D denotes a lane loaded with a molecular weight marker. [E]
Total inositol phosphate (IP) formation in ventricles from RGS2 TG (open
bars, n=3) and dTG mice (n=4 each; closed bars). Freshly dissected
tissue pieces were incubated for 30 min in the absence (basal) or
presence of endothelin-1 (ET-1, 100 nM). # P,0.05 dTG vs RGS2 TG. [F]
H&E stained four-chamber sections of hearts from a 12-week-old wild-
type (WT) and dTG (L1) mouse. [G] Quantitative Western blot analysis of
crude ventricular homogenates from dTG mice: (a) RGS2 protein
suppression within 4 days after Doxycycline (Dox, 100 mg/kg)
administration. (b) RGS2 re-expression in mice, which had received
Dox (100 mg/kg) from gestation until 3 weeks of age, after indicated
weeks of withdrawal from Dox (closed bars, n=4 each); untreated 11
week-old dTG controls (- Dox, open bar, n=5) are shown for
comparison.
doi:10.1371/journal.pone.0040048.g001
Inducible Cardiac-Specific RGS2 Expression in Mice
PLoS ONE | www.plosone.org 2 July 2012 | Volume 7 | Issue 7 | e40048withdrawal compared to untreated dTG mice of the same age
(panel b).
Taken together, the new binary RGS2 transgenic mouse model
showed the expected characteristics with regard to cardiac
specificity and Dox sensitivity of RGS2 expression and its
functionality. We selected WT mice (gender-matched littermates)
as controls for dTG mice after pilot experiments confirmed that
single tTA and single RGS2 transgenic mice had similar cardiac
weights compared to WT mice both under basal conditions and in
response to pressure overload (data not shown).
Effect of RGS2 Expression in vivo on Gq/11-mediated
Hypertrophy Development and LV Function
We determined the effect of both conditional and constitutive
transgenic RGS2 overexpression on hypertrophy development in
response to pressure overload and angiotensin II (Ang II) infusion,
which activates Gq/11-coupled AT1 receptors directly. As ex-
pected, in WT mice TAC - when applied for 1, 4 and 8 weeks -
induced characteristic increases in ventricular weight/body weight
ratios (Figure 2A, panel a, top) and ANF mRNA expression
(bottom). The TAC-induced changes in dTG, irrespective of TAC
duration and the timing of transgenic RGS2 expression, were not
attenuated compared to WT as hypothesized but comparable (or
slightly enhanced after 8 wks TAC only). In response to Ang II
infusion for 12 days (Figure 2A, panel b), the hypertrophic
response in WT was more pronounced than that observed after
TAC (141% vs. 123% increase in VW/BW; 35-fold vs. 3-fold
increase in ANF expression). Again, dTG mice had a comparable
response to WT mice. Taken together, these data demonstrate
that Gq/11-mediated hypertrophy development is not attenuated in
mice with cardiomyocyte-specific RGS2 overexpression in vivo.
Similar results were observed in mice from RGS2 transgenic mice
from L12 (constitutive RGS2 expression, 10 day TAC, data not
shown), which strongly suggests that random insertion of the
transgene into the genome does not contribute to the observed
phenotype.
We next assessed cardiac in vivo hemodynamics in WT and dTG
mice (L1) 1 wk or 8 wks after sham operation or TAC. Mean
heart rates during the measurements ranged from 470 to 542 bpm
in WT and dTG mice with no differences between sham and TAC
(data not shown). Representative PV loop recordings from WT
mice in response to preload reduction are shown in Figure 2B
(panel a). WT mice showed characteristic increases in end-systolic
pressure (panel b) and arterial elastance (which reflects total
ventricular afterload, panel c), a progressive reduction in stroke
volume and ejection fraction (panels d/e) and a steepening of the
end-systolic pressure volume relationship (indicating increased
contractility after 1 wk TAC) that was comparatively blunted after
8 wks (panel f). In dTG mice, both systolic and diastolic functions
were comparable to WT mice under baseline conditions and in
response to short- and long-term TAC. The only exception was
a slight increase in end-systolic pressure after 8 wks TAC that
correlated with a modest increase in pressure gradient (data not
shown). These data demonstrate that regardless of the duration of
TAC, functional responses to pressure overload were not altered in
RGS2-expressing mice compared to WT.
Effect of RGS2 Expression in vivo on Gq/11-mediated PLCb
Activation in Response to TAC
Next, we determined whether transgenic RGS2 was still
functionally active in inhibiting cardiac Gq/11 signaling in dTG
ventricles after TAC (Figure 3A, panel a). To measure basal and
Gq/11-coupled receptor-induced PLCb activity in left and right
ventricles from dTG and WT mice 6 wks after they had been
subjected to TAC (or sham operation), we incubated small tissue
pieces from both chambers for 30 min in the absence or presence
of endothelin-1 (100 nM). ET-1 caused a comparable increase in
PLCb activity in both ventricles in WT, with no major differences
between sham and TAC operation. In both LV and RV,
transgenic RGS2 expression in sham-operated dTG mice did
not alter basal PLCb activity but inhibited ET-1-induced PLCb
activity. Importantly, the inhibitory effect of RGS2 was no longer
observed after TAC.
Since a-MHC- promoter driven transgenes are also expressed
in atrial tissue, we also assessed basal and ET-1-induced PLCb
activity in atrial appendages from the same animals (Figure 3B,
panel a). While basal activity was slightly higher in WT atrial
appendages than ventricles (see legend for Figure 3), the
stimulatory effect of ET-1 was overall comparable. In dTG
atrial appendages, we observed marked inhibition of ET-1-
induced PLCb activation in sham-operated dTG mice that in
contrast to the ventricles was preserved after TAC. Basal PLCb
activity was slightly diminished in dTG atrial tissue but not
ventricles. Panel b in Figures 3A and 3B depict the inhibitory
effect of transgenic RGS2 expression on ET-1-induced PLCb
activity in ventricles and atrial appendages, respectively, in-
dependent from the basal activity. We calculated the difference
in ET-1-induced IP formation and basal IP formation in dTG
for each region both after sham and TAC and expressed it
relative to the respective response in WT, which was set as
100%. In sham-operated RGS2-expressing ventricles, ET-1-
induced PLCb activation was inhibited to 5165% (LV) and
54613% (RV) of WT (P,0.05). After TAC, the inhibitory effect
was marginal and not significant (89630% and 80618% of WT,
respectively). In LA and RA, PLCb inhibition was more
pronounced than in ventricles (3168% and 2567% of WT,
respectively) and preserved after TAC (4267% and 3768% of
WT). Taken together, the response of ventricles and atrial
appendages to transgenic RGS2 expression differed with regard
to (i) its effect on basal PLCb activity (reduced in atrial
appendages but not ventricles), (ii) the extent of inhibition of
Gq/11-mediated PLCb activation (more pronounced in atrial
appendages than ventricles) and (iii) preservation of the inhibitory
RGS2 effect after TAC (in atrial appendages but not ventricles).
Expression of RGS2 (and Other RGS Proteins) and their
Regulation by TAC and Ang II
We examined RGS2 protein and mRNA expression in dTG
mice from L1 (Figure 4A–D) and L12 (Figure 4E/F) as
a potential explanation for the lack of Gq/11 signal inhibition
and hypertrophy in dTG ventricles as well as for the chamber-
specific differences we observed in the effectiveness of RGS2-
mediated inhibition of Gq/11 signaling. First, we addressed in L1
mice whether RGS2 expression is altered in response to TAC
or Ang II infusion. As shown by a representative Western blot
(Figure 4A) and group data (Figure 4B), RGS2 protein was
markedly down-regulated in LV crude homogenates as early as
1 wk after TAC, which persisted until 8 wks (52617% and
56612% compared to sham Ctr, respectively). This effect was
accompanied by corresponding decreases in mRNA expression
at both time points (Figure 4C). Similar RGS2 down-regulation
was observed after Ang II infusion (Figure 4C). Importantly,
despite the TAC-induced decrease in RGS2 expression in dTG,
the overall expression level of RGS2 in dTG was still markedly
enhanced over endogenous RGS2 in WT on both protein and
mRNA level (Figure 4A/D).
Inducible Cardiac-Specific RGS2 Expression in Mice
PLoS ONE | www.plosone.org 3 July 2012 | Volume 7 | Issue 7 | e40048Figure 2. dTG and WT mice have comparable hypertrophic and functional responses to TAC and Ang II. [A] Hypertrophic response to
pressure overload (panel a) and Ang II infusion (panel b): Ventricular weight (normalized to body weight, top panel) and ANF mRNA (normalized to
18S and expressed relative to sham controls, bottom panel) in wild-type mice (WT) and double transgenic mice (dTG, L1) with conditional or
constitutive RGS2 transgene expression after transverse aortic constriction (TAC, n=10–18 WT and n=11–15 dTG) or Ang II infusion (n=9 each) for
indicated durations (solid bars). Animals subjected to sham operation (n=9–15 WT and n=7–9 dTG) or vehicle (saline, n=5–6 each) were used for
comparison (cross-hatched bars). ANF expression was assessed at least in half of the animals in each group. * P,0.05 TAC vs sham (a) or Ang II vs
vehicle (b); # P,0.05 dTG vs WT. [B] In vivo hemodynamic assessment of left ventricular function: (a) Representative pressure volume (PV) recordings
during preload reduction via inferior vena cava compression in WT mice that had been subjected to TAC or sham operation 4 wks earlier. The traces
Inducible Cardiac-Specific RGS2 Expression in Mice
PLoS ONE | www.plosone.org 4 July 2012 | Volume 7 | Issue 7 | e40048Figure 4E (left) illustrates that in dTG L12 mice RGS2 protein
levels were higher in both ventricles (see also Figure 1A) and
atria compared to L1 and that transgenic RGS2 expression was
higher in the atria than ventricles in both lines. These differences
in expression allowed us to indirectly address whether regional
differences in transgene expression could account for the
differences in functional activity of RGS2 we observed in the
different cardiac regions (atria . ventricles, see Figure 3). This
does not seem to be the case, because in spite of greater RGS2
expression, the inhibitory effect on ET-1 induced PLCb
activation in L12 dTG LV and LA was comparable to that in
L1 dTG (Figure 4E, right panel). Figure 4F shows the effect of
TAC on RGS2 mRNA expression in each chamber from L12
dTG mice. RGS2 down-regulation was observed in LV as well
as in LA. In contrast, RGS2 expression in RA was not altered.
Similar results were observed in atrial appendages from L1 dTG
mice (not shown). RGS2 expression in the RV was more variable
in both sham and TAC mice and did not reach statistical
significance.
Taken together, RGS2 protein and mRNA in dTG are marked
down-regulated in LV and LA after TAC and Ang II infusion.
The reduction in RGS2 expression in response to the hypertrophic
stimulus was rapid (within 1 wk) and persistent (until 8 wks). The
remaining levels were still significantly enhanced compared to
non-transgenic controls. Region-specific differences in RGS2
expression levels and its regulation by TAC were observed.
show raw data before subtraction of volume from parallel conduction. The solid lines indicate end-systolic pressure volume relationship (ESPVR). (b)
Group data obtained from PV loop analyses for indicated parameters in WT and dTG mice with conditional RGS2 expression (L1) after TAC for 1 wk
(n=11 WT and n=8 dTG) or 8 wks (n=13–15 WT and n=8–9 dTG) compared to respective sham controls (1 wk: n=9 WT and n=5 dTG; 8 wks:
n=7–8 WT and n=5–6 dTG). * P,0.05 TAC vs Sham; # P,0.05 dTG vs wt.
doi:10.1371/journal.pone.0040048.g002
Figure 3. Transgenic RGS2 expression in vivo differentially inhibits Gq/11-mediated PLCb activation in ventricles and atrial
appendages. Basal (Bas) and Endothelin-1 (ET-1)-induced (100 nM, 30 min) total inositol phosphate (IP) formation in left and right ventricles [A]a s
well as left and right atrial appendages [B] from WT mice (open bars) and dTG mice (L1, constitutive RGS2 expression, closed bars) 6 wks after sham-
operation (cross-hatched bars, n=5 WT and dTG each) or TAC (solid bars, n=4 WT and n=6 dTG). Data are expressed in % of basal values in WT for
each region (panel A: 18–25 cpm/mg tissue for LV and RV after sham or TAC; panel B: 100-140 and 55–85 cpm/mg for LA and RA after sham or TAC,
respectively). *P,0.05 ET-1 vs basal; #P,0.05 dTG vs WT (ET-1 effect);ˆP,0.05 dTG vs WT (basal). The right panels (b) depict the inhibition of ET-1-
induced IP formation (i.e., difference in IP formation in the presence or absence of ET-1 in the respective panel a) in indicated regions of dTG mice.
Data are expressed in % of the ET-1-induced response in WT (set at 100%, not shown). #P,0.05 dTG vs WT.
doi:10.1371/journal.pone.0040048.g003
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the expression of other RGS proteins. RGS4 and RGS5 mRNA
levels were comparable in ventricles from dTG and WT mice
(after sham operation or TAC, Figure 4D). In dTG and WT
atrial appendages (data not shown), we observed a slight
reduction in RGS5 mRNA and comparable levels of RGS4 and
Figure 4. TAC and Ang II induce chamber-specific down-regulation of transgenic RGS2 protein and mRNA. [A] Representative Western
blot of crude ventricular homogenates (60 mg/lane) from WT and dTG (L1) ventricles after sham or 8 wk TAC, which were probed with antibodies
recognizing RGS2 (1 and 10 sec exposure times) and GAPDH. [B] Ventricular RGS2 protein downregulation in dTG mice (L1, conditional transgene
expression) after TAC for 1 wk (n=9) or 8 wks (n=15) compared to respective sham controls (n=7–9). * P,0.05 TAC vs Sham. [C] Ventricular RGS2
mRNA downregulation in dTG mice (L1, conditional transgene expression) after TAC for 1 wk (n=6) or 8 wks (n=12) compared to respective sham
controls (n=6–8). The effect of Ang II infusion (n=4) compared to vehicle controls (n=2) for 12 days is also shown. * P,0.05 TAC vs Sham or Ang II vs
vehicle respectively. [D] Ventricular RGS2, RGS4 and RGS5 mRNA expression in WT and dTG (L1) mice 8 wks after TAC or sham operation. Real-time
PCR data normalized to 18S are expressed relative to respective WT sham (n=7–10 in each group, except for n=3 for RGS2 in WT). [E] Left:
Representative Western blot of crude homogenates (30 mg/lane) of L12 and L1 dTG ventricles (V) and atrial appendages (A) probed with antibodies
recognizing RGS2 and GAPDH. Right: Inhibition of ET-1-induced IP formation in left atrial appendages (LA) and ventricles (LV) from sham-operated
L12 (n=6–7) and L1 (n=5) dTG. Data are expressed in % of the ET-1-induced response in WT (set at 100%, not shown). # P,0.05 dTG vs WT (set at
100%). [F] RGS2 mRNA expression in left and right ventricles and atrial appendages from dTG L12 mice (constitutive transgene expression) 10 days
after TAC compared to respective sham controls (n=5–7). * P,0.05 TAC vs Sham.
doi:10.1371/journal.pone.0040048.g004
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atria [21,22].
Discussion
Hypertrophy is a well-established risk factor for cardiovascu-
lar morbidity and mortality [23,24]. While the initial hypertro-
phic response to hemodynamic stress was long viewed as
a necessary compensatory effect, it has been shown that
hypertrophy is not necessarily required to preserve heart
function [25–27]. Many different strategies have been pursued
to inhibit and/or reverse pathological hypertrophy [2,28,29]. It
is believed that leveraging endogenous negative regulators of
hypertrophy may represent a promising strategy, because it can
mimic negative feedback mechanisms that are often central for
maintaining cellular homeostasis [30,31]. The present study was
designed to test whether overexpression of RGS2 in cardio-
myocytes in vivo can be used as a strategy to inhibit pressure
overload hypertrophy in mice by modulating the finely tuned
Gq/11 signaling pathway. Using a novel mouse model with
cardiomyocyte-specific and inducible transgenic RGS2 expres-
sion, our study suggests that this may not be the case for
reasons that are not yet fully understood. We demonstrate that
transgenic RGS2 is highly functional in negatively regulating
Gq/11 signaling in atrial appendages and to a lesser extent in
ventricles. In ventricles (but not atrial appendages), RGS2-
mediated modulation of Gq/11 signaling was absent after TAC,
which may account for the lack of anti-hypertrophic effect.
Importantly, TAC-induced RGS2 expression changes (down-
regulation) do not seem to underlie the functional differences we
observed between atria and ventricles. Similar results were
observed in two independent transgenic lines, making it highly
unlikely that random insertion contributed to the phenotype in
this model. Changes in the expression of other RGS proteins
are also unlikely to play a role.
We used a well characterized binary Tet-off system [19] to
generate a new mouse model that shows characteristic cardiac-
specific, tTA-dependent and doxycycline-regulatable RGS2 trans-
gene expression. It has been reported that depending on the
expression level, tTA expression itself can have phenotypic effects
in the myocardium [19,32]. In this study, crossbreeding was
performed using tTA transgenic mice with a very low level of tTA
expression, which is sufficient to activate expression of the
responder gene but does not alter cardiac weight or function
[19]. Since Dox exposure can also affect the hypertrophic response
in mice [33,34], we compared animals that had been subjected to
the same Dox treatment.
Transgenic RGS2 was robustly overexpressed in heterozygous
dTG mice, but it was reduced on both mRNA and protein levels
after TAC. The extent of down-regulation in our model was
substantial (up to 48%) and was detected as early as 1 wk after
TAC and maintained until 8 wks after TAC. The time course and
magnitude of the RGS2 transgene reduction we observed is not
without precedent. For example, a 40% reduction in a-MHC
driven b2-receptor transgene expression was reported 1 and 3 wks
after TAC, with further reduction (by 70%) upon prolonged TAC
(8 wks), which correlated with a progression in hypertrophy
development [35]. In our model, we did not observe a further
increase in the TAC-induced rise in ventricular weight or ANF
expression between 1 and 8 wks, which is characteristic for FVB
mice [36,37] and different from C57BL/6 mice [37], the strain
used by the other group [35].
Transcriptional regulation could be involved in RGS2 down-
regulation after TAC in dTG mice, since RGS2 mRNA and
protein levels were affected to a similar extent. Changes in RGS2
mRNA stability may contribute as well, since endogenous RGS2
mRNA in WT mice, which is driven by its own promoter, is also
subject to TAC-induced down-regulation in ventricles [14] (see
also Figure 4D). Additional changes in protein stability cannot be
excluded.
Little is known from other studies about region-specific
differences in a-MHC promoter driven transgene expression and
its regulation by experimental in vivo stimuli. We show differences
in RGS2 transgene expression (greater in atria than in ventricles)
as well as its regulation by TAC (marked downregulation in both
LV and LA, with little and no effects in RV and RA, respectively).
Our findings have potentially important implications for other
studies that use the a-MHC promoter to drive transgene
expression. While identifying the underlying mechanisms is
beyond the scope of this investigation, our study points to the
importance of evaluating transgene expression in all regions of the
heart as well as in response to experimental stimuli, since
chamber-specific differences and regulation of transgene expres-
sion may contribute to the phenotype.
RGS2 is generally believed to be selective in negatively
regulating Gq/11 in the heart, which has been attributed to the
geometry of its Ga-binding pocket and three evolutionary highly
conserved amino acids (reviewed in [5]). In some cell types and
under certain experimental conditions, RGS2 has been shown
to suppress AC directly [10,38] and to inhibit Gi/o signaling
[39]. In adult rat ventricular myocytes, RGS2 overexpression
does not affect forskolin- or isoproterenol-induced cAMP
generation [11], indicating that neither direct nor indirect
RGS2-induced AC regulation plays a major role in differenti-
ated myocytes. RGS2 also does not regulate muscarinic Gi/o-
mediated inhibition of cAMP in adult ventricular myocytes [11].
A potential role as terminator of b2-receptor-coupled Gi
signaling was recently proposed for cultured rat ventricular
myocytes [40].
We previously demonstrated that the presence of a FLAG
epitope at the N-terminus of RGS2 does not affect its ability to
negatively regulate Gq/11-mediated IP formation [20]. We also
showed that overexpression of FLAG-tagged RGS2 in neonatal
and adult ventricular myocytes attenuated the stimulatory effects
of ET-1 and phenylephrine on IP formation [11]. In the present
study, we show that transgenic RGS2 expression markedly
inhibited ET-1-induced IP formation compared to controls in
atrial appendages of dTG mice, indicating that transgenic RGS2
at the level expressed in our model is highly functional in vivo.
Effective inhibition of Gq/11 signaling by transgenic RGS2
expression in LA and RA was observed both under basal
conditions (sham controls) and after TAC, when transgenic
RGS2 expression was markedly down-regulated in LA (but not
in RA). Conversely, further enhanced RGS2 expression (as seen in
dTG L12 mice) did not further increase the inhibitory effect of
RGS2 on Gq/11 signaling (compared to L1 dTG). Taken together,
these findings suggest RGS2 in our model is expressed in excess,
allowing for a ‘‘reserve’’ that seems to ensure effective Gq/11
signaling inhibition after TAC-induced RGS2 downregulation in
LA. Given the level of RGS2 overexpression in our mouse lines,
this is not surprising.
In dTG ventricles, the inhibitory effect of transgenic RGS2
was less pronounced than in atrial appendages under sham
conditions. It is unlikely that this is due to lower RGS2
expression in ventricles than in atria, because the inhibitory effect
was not enhanced in L12 dTG ventricles, in which ventricular
RGS2 expression levels was comparable to atrial expression level
in L1 mice. Importantly, after TAC, the inhibitory effect of
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significant. Counter-regulatory changes in ventricular expression
of other Gq/11-regulating RGS proteins were excluded as
potential explanation. While some highly expressed proteins
can be non-functional due to aberrant location, insufficient
posttranslational modifications or other causes, this does not
appear to be the case in our model because of the marked
inhibition of Gq/11 signaling we observed in atrial appendages
with similar expression levels as in ventricles.
The lack of inhibitory effect on Gq/11 signaling in the ventricles
after prolonged TAC was associated with (and likely contributes
to) the lack of anti-hypertrophic effect observed in dTG mice
expressing RGS2. Importantly, irrespective of the duration of
TAC (acute vs. prolonged) and the timing of RGS2 expression
(conditional vs. constitutive), the hypertrophic response to pressure
overload was not attenuated in dTG mice. Although TAC-
induced pressure overload effects are largely mediated by Gq/11
[3,4], we also determined the effect of Ang II, which exerts its
effects primarily via Gq/11-receptor coupled AT1 signaling.
Differential inhibitory effects on Ang II- and TAC-induced
hypertrophy (abrogated vs. no change, respectively) have been
reported in other mouse models (e.g., [41]). In our model, we
observed a comparable increase in LV mass and ANF induction
between dTG and WT in response to Ang II infusion.
Our findings are surprising in light of the fact that endogenous
RGS2 protein is a well recognized, functionally important negative
regulator of Gq/11 signaling and hypertrophy in cardiomyocytes.
This has been shown in vitro using RNA interference in cultured
ventricular cardiac myocytes [14] as well as in vivo in mice with
a global RGS2 knockdown [15]. The latter study showed that
endogenous RGS2 is required for inhibiting the Gaq/11/PLCb
pathway, particularly in the early compensatory phase of pressure
overload (within 1 week), because its absence was associated with
rapid decompensation and increased mortality.
We and others previously demonstrated that transgenic RGS2
overexpression in ventricular myocytes is highly effective in
selectively mitigating the Gq/11-mediated PLCb activation and
the resulting hypertrophic response [11,16]. At the levels
expressed in our model, RGS2 was highly functional in the
atrial appendages, but much less active in the ventricles under
normal conditions and even further reduced after TAC. The
reasons are not yet understood. Differences between atrial and
ventricular RGS2 expression levels do not appear to be the
explanation. Our findings point towards the possibility that
RGS2 function may be differentially regulated in atria and
ventricles in vivo, which could include differences in post-
translational modifications that can modulate the effectiveness of
RGS2 in exerting regulatory effects on GPCR signaling (such as
phosphorylation [42,43] and palmitoylation [44,45]). Beyond the
scope of the present study, our observations warrant further
investigations into potential differences in RGS2 signaling, its
regulation and underlying mechanisms between atrial and
ventricular myocytes, which are known to differ in structure,
function, gene expression and their responses to stimuli (e.g.,
[46,47]).
Since transgenic overexpression of RGS2 was associated with
highly effective inhibition of Gq/11 signaling in the atria, the new
model should be useful for future studies aimed at advancing
understanding of atrial signaling as well as mitigating Gq/11
signaling in the atrium for potential therapeutic purposes.
Targeting Gq/11 signaling in the atria was recently proposed as
a therapeutic strategy to prevent atrial structural and electrical
remodeling and atrial fibrillation [48]. This notion is based on
evidence from both animal models [49,50] and humans [51,52]
that implicate enhanced Gq/11 signaling activation in the
pathogenesis of atrial arrhythmogenic remodeling.
Materials and Methods
Ethics Statement
All animal procedures were approved by the Institutional
Animal Care and Use Committees of Rhode Island Hospital
(protocol # 324-05, 197-08, 117-11) and Brown University
(protocol # 25-07,44-08, 0903027,1003012) and performed in
strict accordance with the recommendations of the Guide for the
Care and Use of Laboratory Animals of the National Institutes of
Health. All surgeries were performed under indicated anesthesia,
and all efforts were made to minimize suffering.
Generation of RGS2 Transgenic Mouse Model
The transgenic construct was generated by PCR amplification
of cDNA encoding mouse RGS2 with a primer pair that
introduced restriction sites and an N-terminal FLAG epitope 59-
ACGCGTCGACATGGACTACAAGGACGACGATGA-
CAAG-39 and 59-CCCAAGCTTTCATGTAG-
CATGGGGCTCCGT-39). The resulting product was subcloned
via Sal I and Hind III restriction digest and ligation into a pBS II
SK(+) expression vector containing an attenuated a-MHC pro-
moter that can be inducibly regulated by tetracycline-controlled
Transactivator (tTA, [19]). After restriction mapping and nucle-
otide sequencing, a linear 7.1-kb DNA fragment was released with
Not I, gel purified (Qiaex II, Qiagen, Valencia, CA) and
microinjected into pronuclei of fertilized FVB mouse oocytes
and implanted in pseudopregnant females by the Transgenic Core
Facilities of Harvard Medical School and Cincinatti Children’s
Hospital. Heterozygous RGS2 transgenic mice (RGS2 TG) mice
were crossed with heterozygous, a-MHC-promoter driven trans-
genic mice expressing a tTA [19]. Genotyping to distinguish wild-
type (WT), RGS2 TG, tTA TG and RGS2/tTA double trans-
genic (dTG) mice was performed using primer pairs that are
specific for transgenic RGS2 (59-CTCCCCCATAAGAGTTT-




59CTTCCCTTTCGTGGAATGTTGATAG-39) as positive con-
trol.
In experiments with conditional RGS2 expression, mice re-
ceived doxycycline (Dox) via food pellets (100 mg/kg, PharmaServ
Inc., Framingham, MA) from gestation until 3 weeks of age to
prevent RGS2 transgene expression during embryonic and
postnatal development (see Fig. 1G, panel a), followed by Dox
withdrawal for at least 8 weeks to allow re-expression of RGS2
transgene expression (see Fig. 1G, panel b) before experiments
were performed. WT mice that were subjected to the same Dox
treatment served as controls. In experiments with constitutive
RGS2 expression, mice did not receive any Dox.
Histology
Hearts were fixed in 4% neutral-buffered formalin, bisected in
a plane that exposed both atria and ventricles, and embedded in
paraffin. Sections (5 mm) were stained with the hematoxylin and
eosin.
Mouse Surgery and Drug Treatment
Pressure overload was induced by transverse aortic constriction
(TAC) as described [53] in 12-15 week old mice that were
anesthetized with pentobarbital (50–70 mg/kg). The body tem-
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3760.5uC via a warm water blanket and a heat lamp controlled
by a TCAT-2AC Animal Temperature Controller. After endo-
tracheal intubation, the mice were connected to a rodent
ventilator (Harvard Apparatus, MiniVent Type 845, Holliston,
MA). Lidocaine (2 mg/kg) was provided in the surgical area as
local anesthetic. An incision was made in the chest wall at the third
intercostal space and a murine rib spreader (a modified Alms
Retractor 2 L inches) was inserted to allow access to the thoracic
cavity. A 7-0 silk suture was applied around the transverse aorta
and a 27-gauge needle. After careful removal of the needle, the rib
spreader was closed, and the lungs reinflated prior to each layer of
closure of the chest wall with 4-0 vicril. Sham controls underwent
the same procedure without aortic constriction. Alzet osmotic
minipumps (no. 2002; Alza Corp, Mountain View, CA) contain-
ing either angiotensin II (Ang II, 1.46 mg/kg ? day) or saline were
surgically implanted subcutaneously between the shoulder blades
under 1–2% isoflurane anesthesia. All mice received 0.4% KCl
post surgery as a standard regimen.
In vivo Hemodynamic Measurements
Left ventricular function was assessed in vivo using pressure-
volume (PV) conductance catheters and a closed chest approach as
described [54,55]. Mice were anesthetized with 1–2% isoflurane
and body temperature was closely monitored and maintained as
described above. Following tracheotomy, mice were ventilated
with 6 ml/kg (animal mass) tidal volume; the respiration rate
(min
21) was calculated as 53.36(animal mass, kg)
20.
26. A Mikro-
TipH PV catheter (PVR-1045, 1F, Millar Instruments Inc.,
Houston, TX) that had been calibrated according to the
manufacturer’s instructions was inserted into the left ventricle
through the right carotid artery and aortic valves. In addition, the
right jugular vein was cannulated with a P10 tube for hypertonic
saline bolus (parallel conduction calibration). Data was acquired
using MPVS Ultra (Millar Instruments Inc.) and PowerLab 16/30
with LabChart 7 Pro software (ADInstrument, Inc., Colorado
Springs, CO). At a sampling rate of 1 kHz, data were recorded
both at steady state and during transient reduction of venous
return (compression of the inferior vena cava by applying
abdominal pressure adjacent to the diaphragm with a cotton Q-
tip). At the end of recordings, pressure gradients between the left
and right carotid arteries were measured by insertion of a second
catheter into the left carotid artery. Data were stored and analyzed
with LabChart 7 and PVAN Ultra softwares by investigators
blinded to genotype. PV relationships at the end of systole and
diastole were derived from recordings after inferior vena cava
occlusion.
Analysis of Protein Expression
Snap-frozen cardiac tissue was homogenized, separated on 4–
10% SDS-polyacrylamide (Tris/glycine) gels and transferred to
nitrocellulose membranes (Protran; Whatman, Piscataway, NJ).
Membranes were stained with Ponceau S to confirm equal loading
(10 or 60 mg/lane), blocked in phosphate-buffered saline (PBS)
containing 5% nonfat dry milk, and then probed with antibodies
against the FLAG epitope (M2, 1:1500; Sigma, St. Louis, MO),
RGS2 (1:800; GenWay Biotech Inc., San Diego, CA), GAPDH
(1:1000, Cell Signaling Technology, Danvers, MA ), or calseques-
trin (CSQ; 1:2500; Thermo Scientific, Rockford, IL). After three
washes with 0.1% Tween 20-containing PBS, nitrocellulose strips
were incubated with appropriate peroxidase-coupled secondary
antibodies. Proteins of interest were visualized by chemilumines-
cence (SuperSignalH West Pico or Femto Substrate; Pierce,
Rockford, IL).
Analysis of mRNA Expression
Total RNA was extracted from snap-frozen ventricular tissue
and atrial appendages using TRIzol reagent (Invitrogen, Carlsbad,
CA). RNA (0.5 mg) was reverse transcribed into cDNA using
TaqManH Reverse Transcription reagents (Applied Biosystems,
Carlsbad, CA). Real-time-PCR (rt-PCR) was performed according
to the manufacturer’s instructions using FAM
TM-labeled Taq-
ManH probes for RGS2, RGS4, RGS5, RGS6, ANF and 18S and
Universal PCR master mix. Each sample was assayed in duplicate
in two independent PCR reactions and normalized to 18S
expression. Samples without template during rt-PCR served as
negative controls. PCR cycling was performed at 95uC for 10 min,
followed by 95uC for 15 s and 60uC for 1 min for a total of 40
cycles using ABI Prism 7900. The cycle threshold (CT) values
corresponding to the PCR cycle number at which fluorescence
emission in real time reaches a threshold above the base-line
emission were determined using sequence detecting system
software (SDS version 2.3; Applied Biosystems). Serial dilutions
of cDNA plasmids for rat RGS2 and RGS5 (0.3 to 3x10
6 copies)
were used to confirm linearity of the resulting CT values.
Phospholipase C b Activity Assay
Total inositol phosphate (IP) formation was measured as
previously described [56]. In brief, freshly dissected atrial and
ventricular small tissue pieces (,3 mg) from both sides of the heart
were labeled for 90 min with myo-[
3H]inositol (4 mCi per 24-well;
GE Healthcare, Piscataway, NJ) in oxygenated (95% O2/5%
CO2) Krebs Henseleit solution containing (in mM) 118 NaCl, 4.7
KCl, 3 CaCl2, 1.2 KH2PO4, 25 NaHCO3, 1.2 MgSO4, 0.5
EDTA, and 10 glucose. After addition of LiCl (10 mM final), the
tissue pieces were incubated in the presence or absence of
endothelin-1 (100 nM) for 30 min at 37uC. Total IP were
extracted with 20 mM formic acid, separated by anion exchange
chromatography (Dowex AG1-X8), and quantitated by liquid
scintillation counting. Data are expressed as cpm/mg tissue, which
we previously demonstrated to correlate with normalization to mg
protein [56].
Statistical Analysis
All values are expressed as mean 6 SEM for indicated numbers
of mice. Group data were compared by one-way or two-way
ANOVA (with genotype and surgery type or treatment as
variables) followed by Bonferroni post-tests for comparison of
replicate means (GraphPad Prism 5). Comparisons between two
groups were performed by unpaired two-tailed Student’s t test. A P
value ,0.05 was considered statistically significant.
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